Breaking News Instant updates and real-time market news.

IBP

Installed Building Products

$84.58 /

+2.98 (+3.65%)

07:43
08/06/20
08/06
07:43
08/06/20
07:43

Installed Building Products reports Q2 adj. EPS $1.12, consensus 75c

Reports Q2 revenue $393.9M, consensus $372.8M. "Despite the unprecedented challenges caused by the COVID-19 health crisis, IBP achieved multiple milestones for the 2020 second quarter including record second quarter sales and profitability," stated Jeff Edwards, Chairman and CEO. "These record results demonstrate the success of our ongoing geographic, end-market, and end-product diversification strategies, the benefits of our pricing strategies, and the hard work and dedication of our employees. In addition, the homebuilding industry has rebounded quickly during the second quarter and we experienced significant growth in our multi-family and commercial end-markets during the quarter. Based on our record second quarter results, current industry backlogs, and our solid liquidity position, we started closing transactions from our strong acquisition pipeline in June. Across our national footprint, our branches continue to follow federal, state, and local requirements in response to COVID-19. At the start of the second quarter, several of our branches where construction was not deemed essential were closed, which impacted revenue by approximately $10 million to $12 million. Operations have resumed across all IBP branches, but several recently re-opened locations are not yet at full capacity. We continue to closely monitor the evolving COVID-19 crisis and we will make the necessary adjustments to protect and support our employees and customers across the country. While overall housing trends have improved significantly from April and May of this year, our single-family market demand may be temporarily impacted by the normal lag between starts and completions as a result of the market disruptions that occurred during the early stages of the pandemic. We believe that IBP's growing presence within the multi-family and commercial end markets and the industry backlog of single-family units under construction, combined with our acquisition strategy, will help us navigate any near-term softness created by the April and May declines in single-family housing starts. Overall, our operating and financial results continue to demonstrate the compelling business model we have created, which has allowed us to effectively respond to recent market conditions, while also providing IBP with a strong platform for long-term value creation," concluded Mr. Edwards.

  • 06

    Aug

  • 12

    Aug

  • 02

    Dec

IBP Installed Building Products
$84.58 /

+2.98 (+3.65%)

07/16/20 BTIG
Installed Building Products, Builders FirstSource price targets raised at BTIG
07/08/20 Truist
SunTrust ups Installed Building Products, TopBuild, Builders FirstSource targets
06/18/20 Benchmark
Installed Building Products price target raised to $87 from $63 at Benchmark
05/27/20 Credit Suisse
Installed Building Products initiated with an Outperform at Credit Suisse

TODAY'S FREE FLY STORIES

Options
Microsoft call buyer realizes 26% same-day gains » 08:00
09/23/20
09/23
08:00
09/23/20
08:00
MSFT

Microsoft

$207.42 /

+4.75 (+2.34%)

Notable profits for the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

07:47 Today Benchmark
Benchmark says Microsoft partnership can be 'big driver' for Kratos
09/22/20 Jefferies
Microsoft deal for Bethesda underscores value of high-quality IP, says Jefferies
09/22/20 Credit Suisse
Microsoft's ZeniMax deal fortifies subscription strategy, says Credit Suisse
09/22/20 Deutsche Bank
Deutsche Bank likes Microsoft acquisition of ZeniMax Media
MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

Recommendations
Aurora Cannabis price target lowered to C$9 from C$18 at MKM Partners » 07:59
09/23/20
09/23
07:59
09/23/20
07:59
ACB

Aurora Cannabis

$7.32 /

+0.99 (+15.64%)

MKM Partners analyst Bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACB Aurora Cannabis
$7.32 /

+0.99 (+15.64%)

ACB Aurora Cannabis
$7.32 /

+0.99 (+15.64%)

05:55 Today Piper Sandler
Aurora Cannabis price target lowered to $8 from $10 at Piper Sandler
09/22/20 Canaccord
Aurora Cannabis price target lowered to C$10 from C$21 at Canaccord
09/21/20 Jefferies
Jefferies upgrades Aurora Cannabis to Hold, cuts price target to C$8.70
09/21/20 Jefferies
Aurora Cannabis upgraded to Hold from Underperform at Jefferies
ACB Aurora Cannabis
$7.32 /

+0.99 (+15.64%)

ACB Aurora Cannabis
$7.32 /

+0.99 (+15.64%)

ACB Aurora Cannabis
$7.32 /

+0.99 (+15.64%)

ACB Aurora Cannabis
$7.32 /

+0.99 (+15.64%)

Recommendations
Massive cost reduction on Tesla's battery front on the horizon, says Wedbush » 07:59
09/23/20
09/23
07:59
09/23/20
07:59
TSLA

Tesla

$423.90 /

-25.41 (-5.66%)

Wedbush analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$423.90 /

-25.41 (-5.66%)

TSLA Tesla
$423.90 /

-25.41 (-5.66%)

07:50 Today Oppenheimer
Tesla should be bought on any near-term weakness, says Oppenheimer
07:28 Today Canaccord
Tesla price target lowered to $377 from $442 at Canaccord
07:26 Today Credit Suisse
Tesla Battery Day plan shows elevated growth narrative ahead, says Credit Suisse
07:24 Today Morgan Stanley
Morgan Stanley says Tesla battery technologies 'bearish for lithium'
TSLA Tesla
$423.90 /

-25.41 (-5.66%)

  • 14
    Feb
TSLA Tesla
$423.90 /

-25.41 (-5.66%)

TSLA Tesla
$423.90 /

-25.41 (-5.66%)

TSLA Tesla
$423.90 /

-25.41 (-5.66%)

Initiation
AssetMark Financial initiated with a Hold at Jefferies » 07:57
09/23/20
09/23
07:57
09/23/20
07:57
AMK

AssetMark Financial

$21.62 /

+0.12 (+0.56%)

Jefferies analyst Gerald…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMK AssetMark Financial
$21.62 /

+0.12 (+0.56%)

AMK AssetMark Financial
$21.62 /

+0.12 (+0.56%)

08/05/20 JPMorgan
AssetMark Financial downgraded on growth slowdown at JPMorgan
08/05/20 JPMorgan
AssetMark Financial downgraded to Neutral from Overweight at JPMorgan
07/15/20 Raymond James
AssetMark Financial price target raised to $31 from $27 at Raymond James
04/14/20 Raymond James
AssetMark Financial price target lowered to $26 from $29 at Raymond James
AMK AssetMark Financial
$21.62 /

+0.12 (+0.56%)

AMK AssetMark Financial
$21.62 /

+0.12 (+0.56%)

Periodicals
Amazon denies formal connection to 'Prime Bike,' The Verge reports » 07:57
09/23/20
09/23
07:57
09/23/20
07:57
AMZN

Amazon.com

$3,128.41 /

+167.41 (+5.65%)

, PTON

Peloton

$94.36 /

-0.395 (-0.42%)

Amazon (AMZN) has denied…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

PTON Peloton
$94.36 /

-0.395 (-0.42%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

07:47 Today Benchmark
Benchmark says Microsoft partnership can be 'big driver' for Kratos
09/22/20 KeyBanc
Echelon Prime Bike not 'significant impediment' to Peloton growth, says KeyBanc
09/22/20
Fly Intel: Top five analyst upgrades
09/22/20 Loop Capital
Global Payments initiated with a Buy at Loop Capital
PTON Peloton
$94.36 /

-0.395 (-0.42%)

09/22/20 KeyBanc
Echelon Prime Bike not 'significant impediment' to Peloton growth, says KeyBanc
09/22/20 Roth Capital
Peloton shares have path to $175, says Roth Capital
09/18/20 JPMorgan
Apple Fitness+ contribution will take time, says JPMorgan
09/16/20 Canaccord
Peloton on its way to connected fitness leadership, says Canaccord
AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

PTON Peloton
$94.36 /

-0.395 (-0.42%)

  • 26
    Sep
AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

PTON Peloton
$94.36 /

-0.395 (-0.42%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

PTON Peloton
$94.36 /

-0.395 (-0.42%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

PTON Peloton
$94.36 /

-0.395 (-0.42%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

Earnings
Centogene sees 2020 revenue EUR60M-EUR65M » 07:55
09/23/20
09/23
07:55
09/23/20
07:55
CNTG

Centogene

$11.08 /

+0.4699 (+4.43%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

  • 10
    Jul
  • 07
    Nov
CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

General news
U.S. MBA reported mortgage applications surged 6.8% in the week ended September 18 » 07:55
09/23/20
09/23
07:55
09/23/20
07:55

U.S. MBA reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
TCF Financial removed from Best Ideas List at Wedbush » 07:54
09/23/20
09/23
07:54
09/23/20
07:54
TCF

TCF Financial

$22.99 /

-0.58 (-2.46%)

Wedbush removed TCF…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TCF TCF Financial
$22.99 /

-0.58 (-2.46%)

TCF TCF Financial
$22.99 /

-0.58 (-2.46%)

06/08/20 BofA
TCF Financial upgraded to Buy from Neutral at BofA
06/08/20 BofA
TCF Financial upgraded to Buy from Neutral at BofA
04/17/20 Wedbush
TCF Financial upgraded to Outperform from Neutral at Wedbush
04/17/20 Wedbush
TCF Financial upgraded to Outperform from Neutral at Wedbush
TCF TCF Financial
$22.99 /

-0.58 (-2.46%)

TCF TCF Financial
$22.99 /

-0.58 (-2.46%)

TCF TCF Financial
$22.99 /

-0.58 (-2.46%)

Earnings
Centogene reports Q2 (EUR0.52) vs. (EUR0.39) last year » 07:54
09/23/20
09/23
07:54
09/23/20
07:54
CNTG

Centogene

$11.08 /

+0.4699 (+4.43%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
  • 10
    Jul
  • 07
    Nov
CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

CNTG Centogene
$11.08 /

+0.4699 (+4.43%)

Recommendations
Marinus Pharmaceuticals price target raised to $28 from $7 at Oppenheimer » 07:53
09/23/20
09/23
07:53
09/23/20
07:53
MRNS

Marinus Pharmaceuticals

$12.56 /

-0.32 (-2.48%)

Oppenheimer analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNS Marinus Pharmaceuticals
$12.56 /

-0.32 (-2.48%)

MRNS Marinus Pharmaceuticals
$12.56 /

-0.32 (-2.48%)

09/15/20 SVB Leerink
First indication looking good for Marinus' Ganaxolone, says SVB Leerink
09/15/20 Oppenheimer
Marinus Pharmaceuticals price target raised to $7 from $6 at Oppenheimer
09/15/20 Cantor Fitzgerald
Marinus Pharmaceuticals price target raised to $8 from $6 at Cantor Fitzgerald
09/15/20 Jefferies
Marinus Pharmaceuticals price target raised to $6 from $4 at Jefferies
MRNS Marinus Pharmaceuticals
$12.56 /

-0.32 (-2.48%)

  • 29
    May
  • 11
    Dec
MRNS Marinus Pharmaceuticals
$12.56 /

-0.32 (-2.48%)

MRNS Marinus Pharmaceuticals
$12.56 /

-0.32 (-2.48%)

Recommendations
Pentair price target raised to $52 from $47 at Oppenheimer » 07:52
09/23/20
09/23
07:52
09/23/20
07:52
PNR

Pentair

$45.38 /

+0.78 (+1.75%)

Oppenheimer analyst Bryan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PNR Pentair
$45.38 /

+0.78 (+1.75%)

PNR Pentair
$45.38 /

+0.78 (+1.75%)

09/16/20 JPMorgan
Pentair price target raised to $55 from $52 at JPMorgan
09/14/20 Citi
Pentair upgraded to Buy from Neutral at Citi
07/24/20 RBC Capital
Pentair price target raised to $44 from $39 at RBC Capital
07/09/20 BofA
Pentair double-upgraded to Buy from Underperform at BofA
PNR Pentair
$45.38 /

+0.78 (+1.75%)

PNR Pentair
$45.38 /

+0.78 (+1.75%)

Recommendations
Tesla should be bought on any near-term weakness, says Oppenheimer » 07:50
09/23/20
09/23
07:50
09/23/20
07:50
TSLA

Tesla

$423.90 /

-25.41 (-5.66%)

Oppenheimer analyst Colin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$423.90 /

-25.41 (-5.66%)

TSLA Tesla
$423.90 /

-25.41 (-5.66%)

07:28 Today Canaccord
Tesla price target lowered to $377 from $442 at Canaccord
07:26 Today Credit Suisse
Tesla Battery Day plan shows elevated growth narrative ahead, says Credit Suisse
07:24 Today Morgan Stanley
Morgan Stanley says Tesla battery technologies 'bearish for lithium'
07:22 Today Baird
Tesla designated a bearish Fresh Pick at Baird
TSLA Tesla
$423.90 /

-25.41 (-5.66%)

  • 14
    Feb
TSLA Tesla
$423.90 /

-25.41 (-5.66%)

TSLA Tesla
$423.90 /

-25.41 (-5.66%)

TSLA Tesla
$423.90 /

-25.41 (-5.66%)

Recommendations
Western Digital reorganization could be precursor to spinoff, says Benchmark » 07:49
09/23/20
09/23
07:49
09/23/20
07:49
WDC

Western Digital

$36.46 /

+0.36 (+1.00%)

After Western Digital…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WDC Western Digital
$36.46 /

+0.36 (+1.00%)

WDC Western Digital
$36.46 /

+0.36 (+1.00%)

07:18 Today Craig-Hallum
Western Digital upgraded to Buy from Hold at Craig-Hallum
09/22/20 Susquehanna
Susquehanna updates estimates for Western Digital and Seagate
09/20/20 Deutsche Bank
Western Digital named short-term buy idea at Deutsche Bank
08/12/20 Deutsche Bank
Micron downgraded to Hold from Buy at Deutsche Bank
WDC Western Digital
$36.46 /

+0.36 (+1.00%)

WDC Western Digital
$36.46 /

+0.36 (+1.00%)

WDC Western Digital
$36.46 /

+0.36 (+1.00%)

WDC Western Digital
$36.46 /

+0.36 (+1.00%)

Recommendations
Benchmark says Microsoft partnership can be 'big driver' for Kratos » 07:47
09/23/20
09/23
07:47
09/23/20
07:47
KTOS

Kratos Defense

$18.88 /

-0.865 (-4.38%)

, MSFT

Microsoft

$207.42 /

+4.75 (+2.34%)

, AMZN

Amazon.com

$3,128.41 /

+167.41 (+5.65%)

Benchmark analyst Josh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KTOS Kratos Defense
$18.88 /

-0.865 (-4.38%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

KTOS Kratos Defense
$18.88 /

-0.865 (-4.38%)

09/22/20
Fly Intel: Top five analyst downgrades
09/22/20 JPMorgan
Kratos Defense downgraded to Neutral on valuation at JPMorgan
09/22/20 JPMorgan
Kratos Defense downgraded to Neutral from Overweight at JPMorgan
08/03/20 Canaccord
Kratos Defense second half catalysts should support shares. says Canaccord
MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

09/22/20 Jefferies
Microsoft deal for Bethesda underscores value of high-quality IP, says Jefferies
09/22/20 Credit Suisse
Microsoft's ZeniMax deal fortifies subscription strategy, says Credit Suisse
09/22/20 Deutsche Bank
Deutsche Bank likes Microsoft acquisition of ZeniMax Media
09/21/20 Jefferies
Microsoft 'doubling down on gaming' with deal, says Jefferies
AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

09/22/20 KeyBanc
Echelon Prime Bike not 'significant impediment' to Peloton growth, says KeyBanc
09/22/20
Fly Intel: Top five analyst upgrades
09/22/20 Loop Capital
Global Payments initiated with a Buy at Loop Capital
09/22/20 Bernstein
Bernstein upgrades Amazon.com to Outperform after 16% pullback
KTOS Kratos Defense
$18.88 /

-0.865 (-4.38%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

  • 19
    Jun
KTOS Kratos Defense
$18.88 /

-0.865 (-4.38%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

KTOS Kratos Defense
$18.88 /

-0.865 (-4.38%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

KTOS Kratos Defense
$18.88 /

-0.865 (-4.38%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

MSFT Microsoft
$207.42 /

+4.75 (+2.34%)

AMZN Amazon.com
$3,128.41 /

+167.41 (+5.65%)

Recommendations
Blueprint Medicines price target raised to $113 from $105 at BMO Capital » 07:45
09/23/20
09/23
07:45
09/23/20
07:45
BPMC

Blueprint Medicines

$87.34 /

+10.1 (+13.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

06:27 Today Barclays
Blueprint Medicines price target raised to $90 from $77 at Barclays
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
07/15/20 Deutsche Bank
Blueprint Medicines price target raised to $95 from $85 at Deutsche Bank
RHHBY Roche
$0.00 /

+ (+0.00%)

05:12 Today Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

  • 23
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$87.34 /

+10.1 (+13.08%)

RHHBY Roche
$0.00 /

+ (+0.00%)

General news
Treasury Market Outlook: equities are extending gains » 07:45
09/23/20
09/23
07:45
09/23/20
07:45

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
KB Home price target raised to $49 from $43 at Wells Fargo » 07:44
09/23/20
09/23
07:44
09/23/20
07:44
KBH

KB Home

$40.51 /

+1.61 (+4.14%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KBH KB Home
$40.51 /

+1.61 (+4.14%)

KBH KB Home
$40.51 /

+1.61 (+4.14%)

07:22 Today RBC Capital
KB Home price target raised to $42 from $36 at RBC Capital
06:27 Today Barclays
KB Home price target raised to $45 from $42 at Barclays
04:50 Today KeyBanc
KB Home downgraded to Sector Weight from Overweight at KeyBanc
09/17/20 Barclays
KB Home price target raised to $42 from $39 at Barclays
KBH KB Home
$40.51 /

+1.61 (+4.14%)

KBH KB Home
$40.51 /

+1.61 (+4.14%)

KBH KB Home
$40.51 /

+1.61 (+4.14%)

Recommendations
Nike price target raised to $135 from $110 at Wells Fargo » 07:42
09/23/20
09/23
07:42
09/23/20
07:42
NKE

Nike

$116.98 /

+3.67 (+3.24%)

Wells Fargo analyst Tom…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NKE Nike
$116.98 /

+3.67 (+3.24%)

NKE Nike
$116.98 /

+3.67 (+3.24%)

07:33 Today Morgan Stanley
Nike price target raised to $152 from $142 at Morgan Stanley
07:32 Today Susquehanna
Nike price target raised to $160 from $150 at Susquehanna
07:22 Today Credit Suisse
Nike price target raised to $154 from $136 at Credit Suisse
07:18 Today Raymond James
Nike price target raised to $140 from $121 at Raymond James
NKE Nike
$116.98 /

+3.67 (+3.24%)

NKE Nike
$116.98 /

+3.67 (+3.24%)

NKE Nike
$116.98 /

+3.67 (+3.24%)

NKE Nike
$116.98 /

+3.67 (+3.24%)

Initiation
Open Lending initiated with a Buy at DA Davidson » 07:41
09/23/20
09/23
07:41
09/23/20
07:41
LPRO

Open Lending

$22.20 /

+1.28 (+6.12%)

DA Davidson analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LPRO Open Lending
$22.20 /

+1.28 (+6.12%)

LPRO Open Lending
$22.20 /

+1.28 (+6.12%)

09/21/20 Canaccord
Open Lending data provides attractive setup exiting Q3, says Canaccord
08/12/20 Canaccord
Open Lending price target raised to $25 from $20 at Canaccord
07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Deutsche Bank
Deutsche Bank starts Open Lending with Buy, $23 price target
LPRO Open Lending
$22.20 /

+1.28 (+6.12%)

LPRO Open Lending
$22.20 /

+1.28 (+6.12%)

Recommendations
HubSpot price target raised to $270 from $245 at Wells Fargo » 07:40
09/23/20
09/23
07:40
09/23/20
07:40
HUBS

HubSpot

$281.85 /

-3.16 (-1.11%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HUBS HubSpot
$281.85 /

-3.16 (-1.11%)

07:29 Today Stifel
HubSpot price target raised to $305 after analyst day at Stifel
07:26 Today Canaccord
HubSpot price target raised to $325 from $285 at Canaccord
07:25 Today RBC Capital
HubSpot price target raised to $328 from $280 at RBC Capital
07:17 Today Raymond James
HubSpot price target raised to $320 from $265 at Raymond James
HUBS HubSpot
$281.85 /

-3.16 (-1.11%)

HUBS HubSpot
$281.85 /

-3.16 (-1.11%)

Hot Stocks
DraftKings appoints Jocelyn Moore, Valerie Mosley to board of directors » 07:39
09/23/20
09/23
07:39
09/23/20
07:39
DKNG

DraftKings

$53.92 /

+2.44 (+4.74%)

DraftKings announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DKNG DraftKings
$53.92 /

+2.44 (+4.74%)

DKNG DraftKings
$53.92 /

+2.44 (+4.74%)

09/22/20 Morgan Stanley
Barstool Sportsbook app 'bullish' for the sector, says Morgan Stanley
09/15/20 Craig-Hallum
DraftKings price target raised to $60 from $48 at Craig-Hallum
09/15/20 Benchmark
DraftKings price target raised to $57 from $45 at Benchmark
09/15/20 Oppenheimer
DraftKings price target raised to $55 from $50 at Oppenheimer
DKNG DraftKings
$53.92 /

+2.44 (+4.74%)

  • 19
    Jun
DKNG DraftKings
$53.92 /

+2.44 (+4.74%)

DKNG DraftKings
$53.92 /

+2.44 (+4.74%)

DKNG DraftKings
$53.92 /

+2.44 (+4.74%)

Initiation
dMY Technology Group initiated with a Buy at Benchmark » 07:39
09/23/20
09/23
07:39
09/23/20
07:39
DMYT

dMY Technology Group

$13.00 /

-0.55 (-4.06%)

Benchmark analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DMYT dMY Technology Group
$13.00 /

-0.55 (-4.06%)

DMYT dMY Technology Group
$13.00 /

-0.55 (-4.06%)

Hot Stocks
Cytokinetics initiates Phase 1 clinical study of CK-3772271 » 07:37
09/23/20
09/23
07:37
09/23/20
07:37
CYTK

Cytokinetics

$20.56 /

-0.75 (-3.52%)

Cytokinetics,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CYTK Cytokinetics
$20.56 /

-0.75 (-3.52%)

CYTK Cytokinetics
$20.56 /

-0.75 (-3.52%)

07/23/20 H.C. Wainwright
Cytokinetics price target raised to $59 from $38 at H.C. Wainwright
07/23/20 Piper Sandler
Cytokinetics price target raised to $36 from $33 at Piper Sandler
07/16/20 Needham
Cytokinetics price target raised to $45 from $34 at Needham
07/15/20 Cantor Fitzgerald
Cytokinetics price target raised to $41 from $29 at Cantor Fitzgerald
CYTK Cytokinetics
$20.56 /

-0.75 (-3.52%)

  • 17
    Jul
CYTK Cytokinetics
$20.56 /

-0.75 (-3.52%)

Downgrade
Carvana downgraded to Neutral from Buy at B. Riley FBR » 07:37
09/23/20
09/23
07:37
09/23/20
07:37
CVNA

Carvana

$226.75 /

+52.96 (+30.47%)

B. Riley FBR analyst Lee…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CVNA Carvana
$226.75 /

+52.96 (+30.47%)

CVNA Carvana
$226.75 /

+52.96 (+30.47%)

06:08 Today JMP Securities
Carvana price target raised to $250 from $200 at JMP Securities
09/22/20 Baird
Carvana price target raised to $240 from $195 at Baird
09/22/20 Stephens
Carvana price target raised to $207 from $165 at Stephens
09/22/20 JPMorgan
JPMorgan ups Carvana to Overweight after 'surprise' profitability acceleration
CVNA Carvana
$226.75 /

+52.96 (+30.47%)

  • 19
    May
CVNA Carvana
$226.75 /

+52.96 (+30.47%)

CVNA Carvana
$226.75 /

+52.96 (+30.47%)

CVNA Carvana
$226.75 /

+52.96 (+30.47%)

Hot Stocks
AGF Management, SAF Group extend partnership for private credit opportunities » 07:36
09/23/20
09/23
07:36
09/23/20
07:36
AGFMF

AGF Management

$0.00 /

+ (+0.00%)

AGF Management announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AGFMF AGF Management
$0.00 /

+ (+0.00%)

AGFMF AGF Management
$0.00 /

+ (+0.00%)

09/21/20 Scotiabank
AGF Management price target raised to C$6 from C$5.75 at Scotiabank
09/17/20 RBC Capital
AGF Management price target raised to C$5.50 from C$5 at RBC Capital
06/25/20 Scotiabank
AGF Management price target lowered to C$5.75 from C$6 at Scotiabank
06/17/20 Barclays
AGF Management price target raised to C$4.50 from C$3 at Barclays
AGFMF AGF Management
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.